Hopp til hovedinnhold
Toggle navigation
Live markets
Search
Search
Search
Search
My profile
My Subscriptions
Watchlists
Quote alerts
Create account
Sign in
NB
FR
EN
PT
NL
NB
DE
IT
Hjem
Company Press Releases
Company press releases
Abonner
Filtre
Filtre
Oppdater
Nullstill
Icon After
Dato
Toggle Visibility
Alle
I dag
Denne uken
Denne måneden
Tilpasset datosøk
Fra
Til
Kategori
Toggle Visibility
Alliances and agreements
Annen informasjonspliktig regulatorisk informasjon
Change in Capital
Commercial operations
Commercial results
Corporate life
Dividend
Eks.dato
Endringer i rettighetene til aksjer / verdipapirer
Flagging
General meeting / Board Meeting
Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll
Ikke-informasjonspliktige pressemeldinger
Income
Innsideinformasjon
Joint venture
Journal / appointments
Kapital- og stemmerettsendringer
Legal
Meetings / events
Meldepliktig handel for primærinnsidere
Mergers, Acquiqitions, Transferts
New
New establishment
News contracts
Other financial transaction
Other subject
Polls / Surveys
Products and services
Prospekt / opptaksdokument
Rapportering om betaling til myndigheter (land-for-land rapportering)
Rating
Renteregulering
Sales
Share history
Share introduction and issues
Takeover bids
Trends / Analyses
Utsteders meldeplikt ved handel i egne aksjer
Valg av hjemstat
Årsrapporter og revisjonsberetninger
Leverandør
Toggle Visibility
ActusNewsWire
BusinessWire
EQS Group
Euronext
GlobeNewswire
Les Echos
Marketwire
Modular Finance
Oslo Børs Newspoint
PR Newswire
Viser 1 - 50 av 174 resultater
Tid
Selskap
Tittel
Sektor
Kategori
07 Dec 2024
18:30 CET
GALAPAGOS
Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
20103010 Biotechnology
Other subject
07 Dec 2024
18:30 CET
GALAPAGOS
Galapagos kondigt bemoedigende nieuwe resultaten aan van de lopende fase 1/2-studie van de CD19 CAR T-celtherapie GLPG5101 bij patiënten met recidief/refractair non-Hodgkin lymfoom
20103010 Biotechnology
Other subject
05 Nov 2024
22:01 CET
GALAPAGOS
Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024
20103010 Biotechnology
Other subject
05 Nov 2024
22:01 CET
GALAPAGOS
Galapagos presenteert resultaten van baanbrekende innovatie in kankerceltherapie op ASH 2024
20103010 Biotechnology
Other subject
30 Oct 2024
21:01 CET
GALAPAGOS
Galapagos rapporteert financiële resultaten over het derde kwartaal van 2024 en geeft een bedrijfsupdate
20103010 Biotechnology
Other subject
30 Oct 2024
21:01 CET
GALAPAGOS
Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update
20103010 Biotechnology
Other subject
07 Oct 2024
07:00 CEST
GALAPAGOS
Galapagos verwelkomt Oleg Nodelman in haar Raad van Bestuur om strategische groei te ondersteunen
20103010 Biotechnology
Other subject
07 Oct 2024
07:00 CEST
GALAPAGOS
Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth
20103010 Biotechnology
Other subject
30 Sep 2024
22:01 CEST
GALAPAGOS
Galapagos ontvangt transparantieverklaring van EcoR1 Capital
20103010 Biotechnology
Other subject
30 Sep 2024
22:01 CEST
GALAPAGOS
Galapagos receives transparency notification from EcoR1 Capital
20103010 Biotechnology
Other subject
16 Sep 2024
22:01 CEST
GALAPAGOS
Galapagos receives transparency notification from EcoR1 Capital
20103010 Biotechnology
Other subject
16 Sep 2024
22:01 CEST
GALAPAGOS
Galapagos ontvangt transparantieverklaring van EcoR1 Capital
20103010 Biotechnology
Other subject
03 Sep 2024
22:01 CEST
GALAPAGOS
Galapagos receives transparency notification from FMR LLC
20103010 Biotechnology
Other subject
03 Sep 2024
22:01 CEST
GALAPAGOS
Galapagos ontvangt transparantieverklaring van FMR LLC
20103010 Biotechnology
Other subject
23 Aug 2024
07:00 CEST
GALAPAGOS
Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma
20103010 Biotechnology
Other subject
23 Aug 2024
07:00 CEST
GALAPAGOS
Galapagos kondigt FDA-goedkeuring aan van IND-aanvraag voor fase 1/2 ATALANTA-1 studie van CD19 CAR-T, GLPG5101, in recidief/refractair non-Hodgkin lymfoom
20103010 Biotechnology
Other subject
20 Aug 2024
22:01 CEST
GALAPAGOS
Galapagos receives transparency notification from FMR LLC
20103010 Biotechnology
Other subject
20 Aug 2024
22:01 CEST
GALAPAGOS
Galapagos ontvangt transparantieverklaring van FMR LLC
20103010 Biotechnology
Other subject
01 Aug 2024
22:01 CEST
GALAPAGOS
Galapagos reports half-year 2024 financial results and provides second quarter business update
20103010 Biotechnology
Other subject
01 Aug 2024
22:01 CEST
GALAPAGOS
Galapagos rapporteert halfjaarcijfers 2024 en geeft een update over de activiteiten in het tweede kwartaal
20103010 Biotechnology
Other subject
14 Jun 2024
22:01 CEST
GALAPAGOS
Galapagos presenteert bemoedigende nieuwe resultaten voor CD19 CAR-T kandidaat GLPG5101 in non-Hodgkin lymfoom op EHA 2024
20103010 Biotechnology
Other subject
14 Jun 2024
22:01 CEST
GALAPAGOS
Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024
20103010 Biotechnology
Other subject
30 May 2024
22:01 CEST
GALAPAGOS
Galapagos en Adaptimmune ondertekenen klinische samenwerkingsovereenkomst met optie om Adaptimmune's TCR T-celtherapiekandidaat, uza-cel, exclusief in te licentiëren voor hoofd- & halskanker en mogelijke toekomstige vaste tumoren indicaties
20103010 Biotechnology
Other subject
30 May 2024
22:01 CEST
GALAPAGOS
Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune’s TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications
20103010 Biotechnology
Other subject
16 May 2024
22:01 CEST
GALAPAGOS
Galapagos creëert nieuwe inschrijvingsrechtenplannen
20103010 Biotechnology
Other subject
16 May 2024
22:01 CEST
GALAPAGOS
Galapagos creates new subscription right plans
20103010 Biotechnology
Other subject
15 May 2024
22:01 CEST
GALAPAGOS
Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ decentralized CAR-T manufacturing network in the U.S.
20103010 Biotechnology
-
15 May 2024
22:01 CEST
GALAPAGOS
Galapagos en Blood Centers of America kondigen een strategische samenwerking aan om Galapagos' gedecentraliseerde CAR-T productienetwerk in de VS versneld op te schalen
20103010 Biotechnology
-
02 May 2024
22:01 CEST
GALAPAGOS
Galapagos reports first quarter 2024 financial results
20103010 Biotechnology
Other subject
02 May 2024
22:01 CEST
GALAPAGOS
Galapagos rapporteert financiële resultaten voor het eerste kwartaal 2024
20103010 Biotechnology
Other subject
30 Apr 2024
22:01 CEST
GALAPAGOS
Galapagos’ shareholders adopt all resolutions proposed by the Board of Directors at the Annual and Extraordinary Shareholders Meetings 2024
20103010 Biotechnology
Other subject
30 Apr 2024
22:01 CEST
GALAPAGOS
Galapagos’ aandeelhouders keuren alle door de Raad van Bestuur voorgestelde besluiten goed op de jaarlijkse Gewone en Buitengewone Algemene Aandeelhoudersvergaderingen 2024
20103010 Biotechnology
Other subject
04 Apr 2024
22:01 CEST
GALAPAGOS
Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024
20103010 Biotechnology
Other subject
04 Apr 2024
22:01 CEST
GALAPAGOS
Galapagos toont innovatieve aanpak in hematologische kankerzorg met presentaties over klinische en translationele data op EBMT congres 2024
20103010 Biotechnology
Other subject
28 Mar 2024
21:01 CET
GALAPAGOS
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
20103010 Biotechnology
Other subject
28 Mar 2024
21:01 CET
GALAPAGOS
Galapagos publiceert 2023 jaarverslag en kondigt jaarlijkse Gewone Algemene en Buitengewone Algemene Aandeelhoudersvergaderingen aan
20103010 Biotechnology
Other subject
26 Mar 2024
21:01 CET
GALAPAGOS
Galapagos benoemt Andrew Dickinson tot Niet-Uitvoerend, Niet-Onafhankelijk Bestuurder van haar Raad van Bestuur
20103010 Biotechnology
Other subject
26 Mar 2024
21:01 CET
GALAPAGOS
Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board
20103010 Biotechnology
Other subject
22 Feb 2024
22:01 CET
GALAPAGOS
Galapagos kondigt 2023 jaarresultaten en vooruitzichten 2024 aan
20103010 Biotechnology
Other subject
22 Feb 2024
22:01 CET
GALAPAGOS
Galapagos announces full year 2023 results and outlook for 2024
20103010 Biotechnology
Other subject
15 Feb 2024
22:01 CET
GALAPAGOS
Galapagos presenteert op de jaarlijkse EBMT-EHA meeting van 2024
20103010 Biotechnology
Other subject
15 Feb 2024
22:01 CET
GALAPAGOS
Galapagos presents at EBMT-EHA annual meeting 2024
20103010 Biotechnology
Other subject
31 Jan 2024
22:01 CET
GALAPAGOS
Galapagos completes transaction to transfer Jyseleca® business to Alfasigma
20103010 Biotechnology
Other subject
31 Jan 2024
22:01 CET
GALAPAGOS
Galapagos rondt transactie af om Jyseleca® business over te dragen aan Alfasigma
20103010 Biotechnology
Other subject
04 Jan 2024
22:01 CET
GALAPAGOS
Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further expand its decentralized CAR-T manufacturing network in the U.S.
20103010 Biotechnology
Other subject
04 Jan 2024
22:01 CET
GALAPAGOS
Galapagos gaat strategische samenwerkingsovereenkomst aan met Thermo Fisher Scientific om gedecentraliseerd CAR-T productienetwerk in de VS verder uit te breiden
20103010 Biotechnology
Other subject
03 Jan 2024
22:01 CET
GALAPAGOS
Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology
20103010 Biotechnology
Other subject
03 Jan 2024
22:01 CET
GALAPAGOS
Galapagos gaat een strategische samenwerking aan met BridGene Biosciences om de ontdekking van kleine moleculegeneesmiddelen in oncologie uit te breiden
20103010 Biotechnology
Other subject
02 Jan 2024
07:00 CET
GALAPAGOS
Galapagos signs agreement to transfer Jyseleca® business to Alfasigma
20103010 Biotechnology
Other subject
02 Jan 2024
07:00 CET
GALAPAGOS
Galapagos tekent overeenkomst om Jyseleca® business over te dragen aan Alfasigma
20103010 Biotechnology
Other subject
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Sider
1
2
3
›
››
»
Last »
Company press releases subscription
×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in
Hjem
Markeder
Amsterdam
Cash Products
Aksjer
AEX index Stocks
AEX ESG Stocks
Indekser
Fond
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksopsjoner
Indeksfutures
Aksjeopsjoner
Utbyttederivater
Aksjefutures
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Brussel
Cash products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
Expert Market
BEL 20 Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Expert Market
Dublin
Stocks
Euronext regulated
Euronext Growth
ISEQ 20 Stocks
Indices
Funds
Bonds
Irish Government Bonds
DOL
Lisboa
Cash Products
Aksjer
Euronext regulated
Euronext Access
PSI Stocks
Indekser
Obligasjoner
Derivater
Indeksfutures
Stock options
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Milan
Cash Products
Stocks
Euronext Milan
Euronext Growth Milan
Euronext Star Milan
Euronext Global Equity Market
EuroTLX
Trading After Hours
MIB ESG Stocks
Bonds
MOT
Euronext Access Milan
EuroTLX
Structured Products
SeDeX
EuroTLX
ETFs
Funds
Derivative products
All derivatives
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
IPOs
Oslo
Aksjer, renter, indekser
Aksjer
Oslo Børs
Euronext Growth
Euronext Expand
Top performers
OBX aksjer
OBX ESG aksjer
OSEBX aksjer
OSEFX Aksjer
Seafood Aksjer
Shipping Aksjer
Aksjeindekser
Obligasjoner
Oslo Børs
Nordic Alternative Bond Market
Obligasjonsindekser
ETFer
Fond
Derivater
Derivative products
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Finanskalender
Primærinnsidere
Paris
Cash Products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
CAC 40 Stocks
CAC 40 ESG Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Aksjer
All Markets directories
All Markets
Euronext regulated
Euronext Growth
Euronext Access
Euronext Expand
Euronext Global Equity Market
EuroTLX
Trading After Hours
Selskapsmeldinger
Latest
Archive
Nye aksjenoteringer
Alle aksjenoteringer
Euronext Growth advisors
Euronext Tech Leaders
Family business
Indekser
Directory
Grønne indekser
Indices documents
Indices news
Indekser høringer
Kontakter Euronext-indekser
ETF-er
Directory
Grønne ETF-er
Fond
Directory
ESG Funds
Oslo Mutual Funds
Obligasjoner
Grønne obligasjoner
1.5° Bonds
All Markets directories
All Markets
Amsterdam
Brussels
Dublin
Lisbon
Oslo
Milan
Paris
Strukturerte produkter
Directory / search
Bid-Only trading status
Trading Turbos in the Netherlands
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
ETF opsjoner
Kontraktsspesifikasjoner
Tick sizes
Rapportering av handler
Leverandørkoder markedsdata
Råvarer
Quotes
Quotes snapshot
Milling Wheat futures
Rapeseed futures
Corn futures
European Durum Wheat Futures
Milling Wheat options
Rapeseed options
Corn options
Bortfallskalendre
Bortfall
Wholesale Trading
Commitments of Traders (CoT) report
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
DSP
Knowledge Centre
Bid & Ask
Options Investing E-learning
Contract Specifications
Position Management
Intrinsic Value
Premium & Valuation
Moneyness
Positions
Euronext News
Ressurser
Statistikk & rapporter
Quality of execution
Åpningstider
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Key Information Document
Class level
Product group level
Notices / Corporate actions
Cash Notices / Corporate actions
Derivatives corporate actions
All Corporate Actions
Latest
Unusual Contract Sizes, Dividends
Corporate Action Services
Corporate Action Policies
Derivatives notices
Markedshendelser
Suspenderte instrumenter
Stressed Market Conditions
Brudd på Double Cap limits
Ekstraordinære markedsforhold
Diverse meldinger
Market status
Medlemsliste
Issuers compliance
Hvor du finner hva